Neurogene: Funding, Investors & Team (Sep 2026)
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit http://www.neurogene.com/careers/.
Neurogene has raised $200M across 1 funding round on record, the most recent an undisclosed round of $200M announced in Nov 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Neurogene Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Neurogene Funding Rounds
Neurogene Founders and Leadership Team
Contact details for the Neurogene team: 1 of 1 has an email address on file.
Start 14-day free trial →Neurogene Funding Compared to Other Biotechnology Startups
Neurogene's latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Neurogene in Biotechnology and New York
Companies Similar to Neurogene
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Neurogene Funding FAQs
What does Neurogene do?
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit http://www.neurogene.com/careers/.
How much funding has Neurogene raised?
Neurogene has raised $200M across 1 round on record. The most recent is an undisclosed round of $200M announced in Nov 2024.
When did Neurogene last raise funding?
Neurogene's most recent funding round on record is an undisclosed round of $200M, announced in Nov 2024.
Who founded Neurogene?
FundedIQ lists Rachel Mcminn (Founder) at Neurogene.
Where is Neurogene headquartered?
Neurogene is based in New York, United States.
How many employees does Neurogene have?
Neurogene is in the 51-100 employee band.
How does Neurogene's funding compare to other Biotechnology startups?
Neurogene's latest round of $200M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Neurogene Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Neurogene is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.